Puma Biotech (PBYI) Tops Q4 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
March 3, 2022 4:05 PM ESTLOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2021. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2021, compared to the fourth quarter and full year 2020.
Product revenue, net consists entirely of revenue from sales of NERLYNX®, Pumas first commercial product. Product revenue, net for the fourth quarter of 2021 was $51.0 million, compared to product revenue, net of $50.0 million in the fourth quarter of 2020. Product revenue, net for the full year 2021 was $189.1 million, compared to... More
